Exact Sciences Corporation

EXASintermediary

Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology. Its Cologuard test has become the leading non-invasive colorectal cancer screening tool, and its multi-cancer early detection test aims to transform cancer diagnosis.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($2.8B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Screening (Cologuard) (55%)

Precision Oncology (Oncotype DX) (35%)

Other / Pipeline (10%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Cologuard (Colorectal Cancer)45%

Non-invasive stool DNA test for colorectal cancer screening

Oncotype DX (Breast Cancer)30%

Genomic test predicting breast cancer recurrence risk

Multi-Cancer Early Detection (MCED)10%

Blood-based test detecting multiple cancer types from a single draw

Lieferkettenbeziehungen

Partner

Pfizer Inc.

Cancer screening combined with pharma treatment

Auswirkung: Low — co-marketing exploration

Eli Lilly and Company

Companion diagnostics for oncology drugs

Auswirkung: Low — diagnostic partnerships

Regeneron Pharmaceuticals

Genomic profiling for antibody therapies

Auswirkung: Low

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Exact Sciences Corporation.

Unternehmensinformationen

Hauptsitz

Madison, Wisconsin, USA

Gegründet

1995

Mitarbeiter

7,200+

Website

exactsciences.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten